Prelude Therapeutics
Wilmington
About Prelude Therapeutics
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer. Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $207.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:PRLD
- Website: preludetx.com
- Phone: (302)467-1280
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/prelude-therapeutics-42422 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.